Literature DB >> 21898720

Enhanced cardioprotective effects by coexpression of two isoforms of hepatocyte growth factor from naked plasmid DNA in a rat ischemic heart disease model.

Woong Hahn1, Wook-Bum Pyun, Dong-Sik Kim, Won-Sun Yoo, Sung-Dong Lee, Jung-Hee Won, Gil Ja Shin, Jong-Mook Kim, Sunyoung Kim.   

Abstract

BACKGROUND: The therapeutic potential of pCK-HGF-X7, a naked DNA designed to express two isoforms of hepatocyte growth factor (HGF(723) and HGF(728) ), was studied in the rat ischemic heart disease model.
METHODS: First, the kinetics of gene expression was examined by injecting pCK-HGF-X7 DNA into the rat heart. Second, the cardioprotective effects were compared between the two naked DNA constructs, expressing a single (HGF(728) ) or both isoforms (HGF(728) and HGF(723) ) of HGF, in the rat ischemic heart disease model. The ischemic injury to the rat heart was created by ischemia-reperfusion in the anterior descending artery. The respective naked DNA constructs were injected into the anterior wall of the rat heart with the ischemia-reperfusion injury. Cardiac function, capillary density and anti-fibrotic activity were compared between the two naked DNA constructs.
RESULTS: The intramyocardial administration of pCK-HGF-X7 resulted in transient and localized HGF expression for 3 weeks. At its peak, approximately 678 pg (per mg of tissue protein) of HGF was produced in the injected heart without an increase of HGF protein level in other tissues, and serum. pCK-HGF-X7 more efficiently improved the left ventricular ejection fraction and the systolic anterior wall thickness, increased the capillary density, and inhibited myocardial fibrosis, in a statistically significant manner, compared to the identical vector encoding HGF(728) only.
CONCLUSIONS: These results demonstrate that transfer of the genomic-cDNA hybrid expressing both isoforms of the HGF gene might provide higher therapeutic effects than the cDNA sequence producing HGF(728) alone in the treatment of ischemic heart disease.
Copyright © 2011 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21898720     DOI: 10.1002/jgm.1603

Source DB:  PubMed          Journal:  J Gene Med        ISSN: 1099-498X            Impact factor:   4.565


  10 in total

1.  Safety and efficacy of plasmid DNA expressing two isoforms of hepatocyte growth factor in patients with critical limb ischemia.

Authors:  M R Kibbe; A T Hirsch; F O Mendelsohn; M G Davies; H Pham; J Saucedo; W Marston; W-B Pyun; S-K Min; B G Peterson; A Comerota; D Choi; J Ballard; R A Bartow; D W Losordo; W Sherman; V Driver; E C Perin
Journal:  Gene Ther       Date:  2015-12-08       Impact factor: 5.250

2.  A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Hepatocyte Growth Factor in the Treatment of Critical Limb Ischemia.

Authors:  Yongquan Gu; Shijun Cui; Qi Wang; Changjian Liu; Bi Jin; Wei Guo; Changwei Liu; Tongbin Chu; Chang Shu; Fuxian Zhang; Chengquan Han; Yue Liu
Journal:  Mol Ther       Date:  2019-10-31       Impact factor: 11.454

3.  Hepatocyte growth factor-modified mesenchymal stem cells improve ischemia/reperfusion-induced acute lung injury in rats.

Authors:  S Chen; X Chen; X Wu; S Wei; W Han; J Lin; M Kang; L Chen
Journal:  Gene Ther       Date:  2016-08-24       Impact factor: 5.250

4.  Noncoding Microdeletion in Mouse Hgf Disrupts Neural Crest Migration into the Stria Vascularis, Reduces the Endocochlear Potential, and Suggests the Neuropathology for Human Nonsyndromic Deafness DFNB39.

Authors:  Robert J Morell; Rafal Olszewski; Risa Tona; Samuel Leitess; Talah T Wafa; Ian Taukulis; Julie M Schultz; Elizabeth J Thomason; Keri Richards; Brittany N Whitley; Connor Hill; Thomas Saunders; Matthew F Starost; Tracy Fitzgerald; Elizabeth Wilson; Takahiro Ohyama; Thomas B Friedman; Michael Hoa
Journal:  J Neurosci       Date:  2020-03-09       Impact factor: 6.167

5.  Phase 1/2 open-label dose-escalation study of plasmid DNA expressing two isoforms of hepatocyte growth factor in patients with painful diabetic peripheral neuropathy.

Authors:  Senda Ajroud-Driss; Mark Christiansen; Jeffrey A Allen; John A Kessler
Journal:  Mol Ther       Date:  2013-04-23       Impact factor: 11.454

6.  Double-blind, placebo-controlled study of HGF gene therapy in diabetic neuropathy.

Authors:  John A Kessler; A Gordon Smith; Bong-Soo Cha; Sung Hee Choi; James Wymer; Aziz Shaibani; Senda Ajroud-Driss; Aaron Vinik
Journal:  Ann Clin Transl Neurol       Date:  2015-03-05       Impact factor: 4.511

7.  Effective control of neuropathic pain by transient expression of hepatocyte growth factor in a mouse chronic constriction injury model.

Authors:  Boram Nho; Junghun Lee; Junsub Lee; Kyeong Ryang Ko; Sung Joong Lee; Sunyoung Kim
Journal:  FASEB J       Date:  2018-04-16       Impact factor: 5.191

8.  Hepatocyte Growth Factor Regulates the miR-206-HDAC4 Cascade to Control Neurogenic Muscle Atrophy following Surgical Denervation in Mice.

Authors:  Wooshik Choi; Junghun Lee; Jaeman Lee; Kyeong Ryang Ko; Sunyoung Kim
Journal:  Mol Ther Nucleic Acids       Date:  2018-07-06       Impact factor: 8.886

9.  Hepatocyte Growth Factor Regulates Macrophage Transition to the M2 Phenotype and Promotes Murine Skeletal Muscle Regeneration.

Authors:  Wooshik Choi; Jaeman Lee; Junghun Lee; Sang Hwan Lee; Sunyoung Kim
Journal:  Front Physiol       Date:  2019-07-25       Impact factor: 4.566

10.  Is There a Link between Basal Metabolic Rate, Spleen Volume and Hepatic Growth Factor Levels in Patients with Obesity-Related NAFLD?

Authors:  Giovanni Tarantino; Vincenzo Citro; Paolo Conforti; Clara Balsano; Domenico Capone
Journal:  J Clin Med       Date:  2019-09-20       Impact factor: 4.241

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.